Prevalence of anti-SARS-CoV-2 antibody in hemodialysis facilities: a cross-sectional multicenter study from Madinah.

Autor:	Housawi AA; From the Ministry of Health, Riyadh, Saudi Arabia., Qazi SJS; From the Saudi Commission for Health Specialties, Riyadh, Saudi Arabia., Jan AA; From the Ministry of Health, King Fahad Hospital, Madinah, Saudi Arabia., Osman RA; From the Internal Medicine Department, Karary University, Omdurman, Sudan., Alshamrani MM; From the Ministry of Health, Riyadh, Saudi Arabia., AlFaadhel TA; From the Department of Internal Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia., AlHejaili FF; From the Department of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia., Al-Tawfiq JA; From the Internal Medicine and Quality Department, Dhahran Health Center, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia., Wafa AA; From the Department of Nephrology, NE Medina Clinic, Madinah, Saudi Arabia., Hamza AE; From the Diaverum, Madinah, Saudi Arabia., Hassan MA; From the Department of Internal Medicine, Hassan Taher Dialysis Center, Madinah, Saudi Arabia., Alharbi SA; From the Ministry of Health, King Fahad Hospital, Madinah, Saudi Arabia., Albasheer H; From the Ministry of Health, King Fahad Hospital, Madinah, Saudi Arabia., Almohmmdi MM; From the Ministry of Health, King Fahad Hospital, Madinah, Saudi Arabia., Alsisi SA; From the Ministry of Health, King Fahad Hospital, Madinah, Saudi Arabia., Mankowski M; From the King Abdullah University of Science and Technology, Thuwal, Saudi Arabia., Van de Klundert J; From the Universidad Adolfo Ibanez, Penalolen, Santiago, Chile., Alhelal AM; From the Ministry of Health, Riyadh, Saudi Arabia., Sala FH; From the Ministry of Health, Riyadh, Saudi Arabia., Kheyami A; From the Laboratories and Blood Banks Administration, General Directorate of Health Affairs of Medina, Madinah, Saudi Arabia., Alhomayeed BA; From the Nephrology Department, Ministry of Health - King Abdulaziz Dialysis Center, Madinah, Saudi Arabia.
Jazyk:	angličtina
Zdroj:	Annals of Saudi medicine [Ann Saudi Med] 2022 Jul-Aug; Vol. 42 (4), pp. 246-251. Date of Electronic Publication: 2022 Aug 04.
DOI:	10.5144/0256-4947.2022.229
Abstrakt:	Background: Since the occurrence of coronavirus disease in 2019 (COVID-19), the global community has witnessed its exponential spread with devastating outcomes within the general population and specifically within hemodialysis patients. Objectives: Compare the state of immunity to SARS-CoV-2 among hemodialysis patients and staff. Design: Cross-sectional study with a prospective follow-up period. Setting: Hemodialysis centers in Madinah region. Patients and Methods: We prospectively tested for SARS-CoV-2 antibodies in dialysis patients using dialysis centers staff as controls. The participants were tested on four occasions when feasible for the presence of anti-SARS-CoV-2 antibodies. We also analyzed factors that might be associated with seropositivity. Main Outcome Measures: SARS-CoV-2 positivity using immunoglobulin G (IgG) levels SAMPLE SIZE: 830 participants, 677 patients and 153 dialysis centers staff as controls. Results: Of the total participants, 325 (257 patients and 68 staff) were positive for SARS-CoV-2 IgG antibodies, for a prevalence of 38.0% and 44.4% among patients and staff, respectively ( P =.1379). Participants with a history of COVID-19 or related symptoms were more likely to have positive IgG ( P <.0001). Surprisingly, positivity was also center-dependent. In a multivariable logistic regression, a history of infection and related symptoms contributed significantly to developing immunity. Conclusion: The high prevalence of SARS-CoV-2 antibody among hemodialysis patients and previously asymptomatic staff suggested past asymptomatic infection. Some centers showed more immunity effects than others. Limitations: Unable to collect four samples for each participant; limited to one urban center. Conflict of Interest: None.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu